Core Viewpoint - Fudan Zhangjiang has reported significant advancements in its R&D investments and clinical trials, particularly in the fields of antibody-drug conjugates (ADC) and photodynamic therapy drugs, indicating a strong potential for future growth and product diversification [1][2] Group 1: R&D Investments - The company invested approximately 358 million RMB in R&D during the reporting period, with a steady increase in the proportion of R&D spending relative to revenue [1] - R&D funding is primarily directed towards ADC and photodynamic drug development, with multiple pipelines achieving key progress [1] Group 2: ADC Developments - The Phase III clinical trial for the FDA018 ADC targeting triple-negative breast cancer has exceeded its enrollment target, with over 350 participants, and data collection is currently underway [1] - The Phase II clinical study for the FDA022 ADC, aimed at HER2 low-expressing breast cancer, has completed patient enrollment and successfully held a communication meeting with regulatory authorities [1] Group 3: Photodynamic Therapy Developments - The application for marketing authorization of the oral solution of aminolevulinic acid for intraoperative visualization in high-grade glioma has been accepted, which could enhance the company's product portfolio and core competitiveness in the photodynamic therapy sector [1] Group 4: Industrialization Support - Fudan Zhangjiang's wholly-owned subsidiary, Taizhou Fudan Zhangjiang, is providing support for the industrialization of its ADC projects, including technology transfer and production process validation [2] - The commercialization of related products is expected to create new growth points for the company, contributing to its long-term high-quality development [2]

Group 1 - Longwood Biotechnologies Inc. holds 13.81 million shares of Zhenghai Biological, accounting for 7.67% of the total shares (7.78% after excluding repurchase) [1] - Longwood plans to reduce its holdings by up to 3.6 million shares within three months from March 23, 2026, to June 22, 2026, representing 2% of the total share capital (2.03% after excluding repurchase) [1] - The reduction will occur through centralized bidding or block trading, with a limit of 1% for bidding and 2% for block trading within any 90 natural days, with prices determined by market conditions [1]

Group 1 - The company Fudan Zhangjiang (01349) reported a revenue of approximately 686 million yuan for 2025, representing a year-on-year decrease of 3.33% [1] - The net loss attributable to shareholders was approximately 157 million yuan, marking a shift from profit to loss compared to the previous year, with a basic loss per share of 0.15 yuan [1] Group 2 - The company actively promoted the progress of R&D projects, with R&D investment accounting for an increasing proportion of revenue, totaling approximately 358 million yuan during the reporting period [2] - The Phase III clinical trial for the FDA018 antibody-drug conjugate for triple-negative breast cancer exceeded enrollment expectations, with over 350 participants enrolled, and data collection is currently underway [2] - The Phase II clinical study for the FDA022 antibody-drug conjugate targeting HER2 low-expressing breast cancer has completed enrollment, and a communication meeting with regulatory authorities was held during the reporting period [2] Group 3 - The company's production and operations remained normal, with no changes in the main types of drugs sold [3] - Due to the inclusion of Doxorubicin Liposome Injection in the national procurement catalog, the company's product, Liposome Doxorubicin, was not selected, prompting a strategic adjustment in its sales approach, including a gradual price reduction starting May 1, 2025, which led to a decrease in profit margins [3]

北京商报讯（记者 王寅浩 宋雨盈）2月27日，昊海生科发布2025年业绩快报，2025年度公司实现营业总 收入24.73亿元，同比减少8.33%；实现归属于母公司所有者的净利润2.51亿元，同比减少40.3%；实现 归属于母公司所有者的扣除非经常性损益的净利润1.6亿元，同比减少57.67%。 ...

Group 1 - The core index of the bio-economy (970038) closed at 2178.02 points, down 0.57%, with a trading volume of 790 million yuan and a turnover rate of 0.06% [1] - Among the constituent stocks, 33 companies saw an increase, with Yingke Medical leading with a rise of 5.08%, while 12 companies experienced a decline, with Changchun High-tech leading the drop at 2.77% [1] Group 2 - The bio-economy index's constituent stocks experienced a net outflow of 253 million yuan from major funds and a net outflow of 208 million yuan from speculative funds, while retail investors saw a net inflow of 461 million yuan [2] - Detailed fund flow information for the constituent stocks is available in the accompanying table [2]

Group 1 - The core viewpoint of the article highlights the potential of Pegbivac to assist more hepatitis B patients in achieving higher treatment goals, as it is the world's first drug aimed at the clinical cure of hepatitis B [1] - The company plans to further expand its international business based on operational conditions in the future [1] - The inquiry from investors reflects the growing interest in overseas business development in the Chinese pharmaceutical industry [1]

格隆汇2月27日丨昊海生物科技(06826.HK)发布2025年度业绩快报。报告期内，集团实现营业收入人民 币24.73亿元，同比减少8.33%；实现归属于母公司所有者的净利润为人民币2.51亿元，同比减少 40.30%；实现归属于母公司所有者的扣除非经常性损益的净利润为人民币1.6亿元，同比减少57.67%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 2025年度業績快報公告 上海昊海生物科技股份有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據 《證券及期貨條例》（香港法例第571章）第XIVA部及《香港聯合交易所有限公司證 券上市規則》第13.09及13.10B條的要求發佈本公告，旨在向本公司股東及公眾人 士提供本公司的財務資料。本公告亦同時在上海證券交易所網站發佈。 本公告所載本集團按照中國企業會計準則編製的截至2025年12月31日止年度（「報 告期」）主要財務數據為初步核算未經核數師審計的數據。本集團報告期的具體財 務數據及經營業績將以本公司截至2025年12月31日止年度經審核之業績公告及本 公司2025年度報告所披露者為準。提請本公司潛在 ...

Group 1 - The company has not achieved operating revenue for the year 2025 [1] - The net profit attributable to the parent company's owners is -153.08 million yuan, with a year-on-year loss increase of 97.08 million yuan [1] - The net profit attributable to the parent company's owners, excluding non-recurring gains and losses, is -175.42 million yuan, with a year-on-year loss increase of 17.37 million yuan [1]

Core Viewpoint - Junshi Biosciences reported a significant increase in total revenue for 2025, driven primarily by the strong sales performance of its core product, Toripalimab injection (brand name: Tuoyi®) in the domestic market [1] Financial Performance - The total revenue for 2025 reached 2.498 billion yuan, representing a year-on-year growth of 28.23% [1] - The net loss attributable to the parent company was 874 million yuan, an improvement from a loss of 1.281 billion yuan in the previous year [1] Product Performance - The increase in revenue was mainly due to the substantial growth in sales of Toripalimab injection in the domestic market [1]